Bhattacharya Indrajit, Maity Deep Kumar, Kumar Amit, Sarkar Sampriti, Bhattacharya Teeshyo, Sahu Amrita, Sreedhar Remya, Arumugam Somasundaram
Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, Chunilal Bhawan, 168 Maniktala Main Road, Kolkata, 700054, West Bengal, India.
School of Biosciences & Technology, Vellore Institute of Technology, Tamil Nadu, Vellore, 632014, India.
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 14. doi: 10.1007/s00210-025-04257-x.
Nonalcoholic fatty liver disease (NAFLD), now known by the name of metabolic dysfunction-associated fatty liver disease (MAFLD), with increased global incidence, has been recognized as a significant metabolic disorder. NAFLD includes a spectrum liver disease from hepatocellular fat accumulation (isolated steatosis) to an advanced form of liver injury known as nonalcoholic steatohepatitis (NASH), which refers to distinct histologic features, including hepatocellular steatosis and injury, necroinflammation, and eventually fibrosis. Nonobese or lean individuals associated with metabolic dysregulation usually demonstrated diverse risk factors compared to obese MAFLD. The presence of normal range body mass index (BMI) and excess visceral adiposity with increased cardiometabolic and renal comorbidities, along with sarcopenia, has been evidenced to be associated with lean MASH. Genetic predispositions accompanying lifestyle and environmental factors contribute to disease initiation and progression. The genetic influence in pathophysiology indicated the significant contributions of the following genes: PNPLA3, TM6SF2, APOB, LIPA, MBOAT7, and HSD17B13, and the impact of their disease-specific variants in the development of obesity-independent MASH. The epigenetic modifications exhibited differential DNA methylation patterns in the genes involved in lipid metabolism, particularly hypomethylation of PEMT. Diet-induced and genetic animal models of lean MASH, including Slc: Wistar/ST rats, PPAR-α, PTEN, and MAT1A knockout mice models, are indicated to be pivotal in the exploration of disease progression and observing the effect of therapeutic interventions. This comprehensive review comprises the molecular and genetic pathophysiology, molecular diagnostics, and therapeutic aspects of lean MASH to enunciate a diagnostic approach that combines detailed clinical phenotyping regarding genomic analysis.
非酒精性脂肪性肝病(NAFLD),现称为代谢功能障碍相关脂肪性肝病(MAFLD),在全球的发病率不断上升,已被公认为一种重要的代谢紊乱疾病。NAFLD包括一系列肝脏疾病,从肝细胞脂肪堆积(单纯性脂肪变性)到一种称为非酒精性脂肪性肝炎(NASH)的晚期肝损伤形式,后者具有独特的组织学特征,包括肝细胞脂肪变性和损伤、坏死性炎症,最终发展为纤维化。与肥胖的MAFLD患者相比,伴有代谢失调的非肥胖或瘦型个体通常表现出多种不同的危险因素。已证实,体重指数(BMI)在正常范围但存在内脏脂肪过多,同时伴有心脏代谢和肾脏合并症增加,以及肌肉减少症,与瘦型MASH相关。生活方式和环境因素伴随的遗传易感性会导致疾病的发生和发展。病理生理学中的遗传影响表明以下基因具有重要作用:PNPLA3、TM6SF2、APOB、LIPA、MBOAT7和HSD17B13,以及它们的疾病特异性变体在不依赖肥胖的MASH发展中的影响。表观遗传修饰在参与脂质代谢的基因中表现出不同的DNA甲基化模式,特别是PEMT的低甲基化。饮食诱导和遗传的瘦型MASH动物模型,包括Slc:Wistar/ST大鼠、PPAR-α、PTEN和MAT1A基因敲除小鼠模型,被认为在探索疾病进展和观察治疗干预效果方面起着关键作用。这篇综述全面阐述了瘦型MASH的分子和遗传病理生理学、分子诊断及治疗方面,以阐明一种结合基因组分析详细临床表型的诊断方法。